AUTHOR=O’Callaghan John Matthew TITLE=Transplant Trial Watch JOURNAL=Transplant International VOLUME=Volume 36 - 2023 YEAR=2023 URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11742 DOI=10.3389/ti.2023.11742 ISSN=1432-2277 ABSTRACT=To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch. The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. This page of Transplant International offers commentaries on methodological issues and clinical implications on two articles of particular interest from the CET Transplant Trial Watch monthly selection. For all high quality evidence in solid organ transplantation, visit the Transplant Library: www.transplantlibrary.com Randomised controlled trial 1 Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study. Sommerer, C., et al Transplantation 2023 [record in progress].This post-hoc analysis of the TRANSFORM study aimed to compare the effect of everolimus (EVR) and reduced calcineurin inhibitor (rCNI) versus standard triple therapy on cardiovascular disease (CVD) outcomes in de novo kidney transplant patients.Participants in the TRANSFORM trial were randomised to either the EVR+rCNI group or the mycophenolic acid (MPA) + standard-exposure CNI (sCNI) group. Participants 2026 de novo kidney transplant recipients.The main outcomes of interest were the incidence of major adverse cardiac event (MACE), cardiac deaths, time-to-event analysis of MACE, CVD risk factors and levels of metabolic parameters.Everolimus is known to worsen post-transplant dyslipidaemia, but it is not clear that this results in poorer cardiovascular outcomes. This post-hoc analysis of the TRANSFORM study, which compared outcomes in kidney transplant patients on standard immunosuppressive therapy vs a everolimus/reduced tacrolimus regimen,